ATP synthasome contributes to efficient energy flux in malignant breast cancer

Porporato PE, Payen VL, Perez-Escuredo J, De Saedeleer CJ, Danhier P, Copetti T, Dhup S, Tardy M, Vazeille T, Bouzin C, et al. A mitochondrial switch promotes tumor metastasis. Cell Rep. 2014;8:754–66. 10.1016/j.celrep.2014.06.043

[6]

LeBleu VS, O’Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, de Carvalho FM, Damascena A, Domingos Chinen LT, Rocha RM, et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014;16:992–1003. 10.1038/ncb3039

[7]

Chiu YH, Lin SA, Kuo CH, Li CJ. Molecular machinery and pathophysiology of mitochondrial dynamics. Front Cell Dev Biol. 2021;9:743892. 10.3389/fcell.2021.743892

[8]

Clemencon B, Babot M, Trezeguet V. The mitochondrial ADP/ATP carrier (SLC25 family): pathological implications of its dysfunction. Mol Aspects Med. 2013;34:485–93. 10.1016/j.mam.2012.05.006

[9]

Chevrollier A, Loiseau D, Chabi B, Renier G, Douay O, Malthiery Y, Stepien G. ANT2 isoform required for cancer cell Glycolysis. J Bioenerg Biomembr. 2005;37:307–16. 10.1007/s10863-005-8642-5

[10]

Jang JY, Choi Y, Jeon YK, Aung KC, Kim CW. Over-expression of adenine nucleotide translocase 1 (ANT1) induces apoptosis and tumor regression in vivo. BMC Cancer. 2008;8:160. 10.1186/1471-2407-8-160

[11]

Jang JY, Kim YG, Nam SJ, Keam B, Kim TM, Jeon YK, Kim CW. Targeting adenine nucleotide Translocase-2 (ANT2) to overcome resistance to epidermal growth factor receptor tyrosine kinase inhibitor in Non-Small cell lung cancer. Mol Cancer Ther. 2016;15:1387–96. 10.1158/1535-7163.mct-15-0089

[12]

Le Bras M, Borgne-Sanchez A, Touat Z, El Dein OS, Deniaud A, Maillier E, Lecellier G, Rebouillat D, Lemaire C, Kroemer G, et al. Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res. 2006;66:9143–52. 10.1158/0008-5472.can-05-4407

[13]

Sullivan R, Pare GC, Frederiksen LJ, Semenza GL, Graham CH. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther. 2008;7:1961–73. 10.1158/1535-7163.mct-08-0198

[14]

Chen C, Ko Y, Delannoy M, Ludtke SJ, Chiu W, Pedersen PL. Mitochondrial ATP synthasome: three-dimensional structure by electron microscopy of the ATP synthase in complex formation with carriers for Pi and ADP/ATP. J Biol Chem. 2004;279:31761–8. 10.1074/jbc.m401353200

[15]

Ahmad Z, Okafor F, Azim S, Laughlin TF. ATP synthase: a molecular therapeutic drug target for antimicrobial and antitumor peptides. Curr Med Chem. 2013;20:1956–73. 10.2174/0929867311320150003

[16]

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

Christina Curtis, Sohrab P. Shah, Suet-Feung Chin et al.

Nature 2012 10.1038/nature10983

[17]

Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90. 10.1016/j.cell.2009.11.007

[18]

Sciacovelli M, Frezza C. Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer. FEBS J. 2017;284:3132–44. 10.1111/febs.14090

[19]

Li B, Zheng L, Ye J, Zhang C, Zhou J, Huang Q, Guo Y, Wang L, Yu P, Liu S, et al. CREB1 contributes colorectal cancer cell plasticity by regulating LncRNA CCAT1 and NF-kappaB pathways. Sci China Life Sci. 2022;65:1481–97. 10.1007/s11427-022-2108-x

[20]

Sanchez-Tillo E, Lazaro A, Torrent R, Cuatrecasas M, Vaquero EC, Castells A, Engel P, Postigo A. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene. 2010;29:3490–500. 10.1038/onc.2010.102

[21]

Bartha A, Gyorffy B. TNMplot.com: A web tool for the comparison of gene expression in Normal, tumor and metastatic tissues. Int J Mol Sci. 2021;22:2622. 10.3390/ijms22052622

[22]

UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses

Darshan S. Chandrashekar, Bhuwan Bashel, Sai Akshaya Hodigere Balasubramanya et al.

Neoplasia 2017 10.1016/j.neo.2017.05.002

[23]

Li CJ, Lin LT, Chu PY, Chiang AJ, Tsai HW, Chiu YH, Huang MS, Wen ZH, Tsui KH. Identification of novel biomarkers and candidate drug in ovarian cancer. J Pers Med. 2021;11:316. 10.3390/jpm11040316

[24]

Chu PY, Tzeng YT, Chiu YH, Lin HY, Kuo CH, Hou MF, Li CJ. Multi-Omics reveals the immunological role and prognostic potential of mitochondrial ubiquitin ligase MARCH5 in human breast cancer. Biomedicines. 2021;9:1329. 10.3390/biomedicines9101329

[25]

Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer

Balázs Győrffy

Computational and Structural Biotechnology Journal 2021 10.1016/j.csbj.2021.07.014

[26]

Hsu HY, Lin JH, Li CJ, Tsang SF, Tsai CH, Chyuan JH, Chiu SJ, Chuang SE. Antimigratory effects of the methanol extract from momordica Charantia on human lung adenocarcinoma CL1 cells. Evid Based Complement Alternat Med. 2012;2012:819632. 10.1155/2012/819632

[27]

Jha P, Wang X, Auwerx J. Analysis of mitochondrial respiratory chain supercomplexes using blue native polyacrylamide gel electrophoresis (BN-PAGE). Curr Protoc Mouse Biol. 2016;6:1–14. 10.1002/9780470942390.mo150182

[28]

Li CJ, Lin LT, Tsui KH. Dehydroepiandrosterone shifts energy metabolism to increase mitochondrial biogenesis in female fertility with advancing age. Nutrients. 2021;13:2449. 10.3390/nu13072449

[29]

Lin SC, Chien CW, Lee JC, Yeh YC, Hsu KF, Lai YY, Tsai SJ. Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells. J Clin Invest. 2011;121:1905–16. 10.1172/jci44362

[30]

Tzeng YT, Tsui KH, Tseng LM, Hou MF, Chu PY, Sheu JJ, Li CJ. Integrated analysis of pivotal biomarker of LSM1, immune cell infiltration and therapeutic drugs in breast cancer. J Cell Mol Med. 2022;26:4007–20. 10.1111/jcmm.17436

[31]

Liao HW, Chen GY, Wu MS, Liao WC, Lin CH, Kuo CH. Development of a postcolumn Infused-Internal standard liquid chromatography mass spectrometry method for quantitative metabolomics studies. J Proteome Res. 2017;16:1097–104. 10.1021/acs.jproteome.6b01011

[32]

Peng Z, Ye M, Ding H, Feng Z, Hu K. Spatial transcriptomics atlas reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment components in colorectal cancer. J Transl Med. 2022;20:302. 10.1186/s12967-022-03510-8

[33]

Tsai HW, Li CJ, Lin LT, Chiang AJ, Chen SN, Wen ZH, Tsui KH. Expression status and prognostic significance of mitochondrial dynamics OPA3 in human ovarian cancer. Aging. 2022;14:3874–86. 10.18632/aging.204050

[34]

Chevrollier A, Loiseau D, Reynier P, Stepien G. Adenine nucleotide translocase 2 is a key mitochondrial protein in cancer metabolism. Biochim Biophys Acta. 2011;1807:562–7. 10.1016/j.bbabio.2010.10.008

[35]

Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018;24:2482–90. 10.1158/1078-0432.ccr-17-3070

[36]

Tommasin L, Carrer A, Nata FB, Frigo E, Fogolari F, Lippe G, Carraro M, Bernardi P. Adenine nucleotide translocator and ATP synthase cooperate in mediating the mitochondrial permeability transition. J Physiol 2025;603:1–17. 10.1113/jp287147

[37]

Mitochondrial membrane potential

Ljubava D. Zorova, Vasily A. Popkov, Egor Y. Plotnikov et al.

Analytical Biochemistry 2018 10.1016/j.ab.2017.07.009

[38]

Jiang L, Xiao L, Sugiura H, Huang X, Ali A, Kuro-o M, Deberardinis RJ, Boothman DA. Metabolic reprogramming during TGFbeta1-induced epithelial-to-mesenchymal transition. Oncogene. 2015;34:3908–16. 10.1038/onc.2014.321

[39]

Caino MC, Chae YC, Vaira V, Ferrero S, Nosotti M, Martin NM, Weeraratna A, O’Connell M, Jernigan D, Fatatis A, et al. Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J Clin Invest. 2013;123:2907–20. 10.1172/jci67841

[40]

Newman RA, Yang P, Pawlus AD, Block KI. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv. 2008;8:36–49. 10.1124/mi.8.1.8

[41]

Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip AA, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018;24:1036–46. 10.1038/s41591-018-0052-4

[42]

Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, Glasauer A, Dufour E, Mutlu GM, Budigner GS, Chandel NS. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife. 2014;3:e02242. 10.7554/elife.02242

[43]

Actin, a Central Player in Cell Shape and Movement

Thomas D. Pollard, John A. Cooper

Science 2009 10.1126/science.1175862

[44]

Kepp O, Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Sukkurwala AQ, Michaud M, Galluzzi L, Zitvogel L, Kroemer G. Anticancer activity of cardiac glycosides: at the frontier between cell-autonomous and immunological effects. Oncoimmunology. 2012;1:1640–2. 10.4161/onci.21684

[45]

Vasan N, Boyer JL, Herbst RS. A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer. Clin Cancer Res. 2014;20:3921–30. 10.1158/1078-0432.ccr-13-1762

Metrics

0

Citations

45

References

Details

Published: Mar 02, 2026
Vol/Issue: 25(1)
License: View

Authors

Y

Yen-Dun Tony Tzeng

Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan; Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung 804, Taiwan

Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan

P

Pei-Yi Chu

School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City 242, Taiwan; Department of Pathology, Show Chwan Memorial Hospital, Changhua 500, Taiwan; Department of Health Food, Chung Chou University of Science and Technology, Changhua 510, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Tainan 704, Taiwan

S

Su-Boon Yong

Department of Allergy and Immunology, China Medical University Children’s Hospital , Taichung,; Research Center for Allergy, Immunology, and Microbiome (A.I.M.), China Medical University Hospital , Taichung,; Department of Medicine, College of Medicine, China Medical University , Taichung,

S

Shih-Chieh Lin

Department of Power Mechanical Engineering, National Tsing Hua University, Hsinchu City 300, Taiwan

32Taipei Veterans General Hospital;

Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung 804, Taiwan; Marine Biomedical Laboratory and Center for Translational Biopharmaceuticals, Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung 813, Taiwan

Division of Breast Surgery, Department of Surgery, Taichung Veterans General Hospital, Taichung 407612, Taiwan; Department of Applied Cosmetology, College of Human Science and Social Innovation, Hungkuang University, Taichung 433304, Taiwan

Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan; Department of Emergency Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan; Department of Pharmacy and Master Program, College of Pharmacy and Health Care, Tajen University, Pingtung 907, Taiwan

C

Chia-Jung Li

Funding

National Science and Technology Council Award: 114-2314-B-075B-013

Kaohsiung Veterans General Hospital Award: 113-061, 113-092, 114-090, 114-048

Taichung Veterans General Hospital Award: 1143907B

VGHUST Joint Research Program Award: 113-G6-1-2, 113-G2-3-1, 114-G6-2-2

Cite This Article

Yen-Dun Tony Tzeng, Yu-Ting Kang, Tzu-Hung Hsiao, et al. (2026). ATP synthasome contributes to efficient energy flux in malignant breast cancer. Molecular Cancer, 25(1). https://doi.org/10.1186/s12943-026-02610-z

ATP synthasome contributes to efficient energy flux in malignant breast cancer

You May Also Like